Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Vascular Biogen. Ord (VBLT)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 42,529
  • Shares Outstanding, K 29,950
  • Annual Sales, $ 13,860 K
  • Annual Income, $ -10,140 K
  • 36-Month Beta -1.86
  • Price/Sales 3.09
  • Price/Cash Flow N/A
  • Price/Book 0.70

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/18
See More
  • Average Estimate -0.12
  • Number of Estimates 1
  • High Estimate -0.12
  • Low Estimate -0.12
  • Prior Year -0.24
  • Growth Rate Est. (year over year) +50.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.32 +5.30%
on 10/15/18
1.78 -21.91%
on 10/02/18
-0.21 (-13.13%)
since 09/14/18
3-Month
1.32 +5.30%
on 10/15/18
2.20 -36.82%
on 07/16/18
-0.76 (-35.35%)
since 07/13/18
52-Week
1.32 +5.30%
on 10/15/18
9.05 -84.64%
on 11/16/17
-4.71 (-77.21%)
since 10/13/17

Most Recent Stories

More News
Data Presented at ECTRIMS 2018 Show Potential of MOSPD2 as a Novel Target for Treatment of CNS Inflammation, Such as Multiple Sclerosis

TEL AVIV, Israel, Oct. 11, 2018 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), announced today that a study entitled "MOSPD2: A Novel Therapeutic Target for the Treatment of CNS Inflammation,"...

VBLT : 1.39 (-2.11%)
VBL Therapeutics Announces Publication of Positive New Data on its Lecinoxoid Drug Candidates for the Treatment of Renal Fibrosis

-- These data, together with positive preclinical NASH data previously presented, support the potential of VBL's lecinoxoid pipeline

VBLT : 1.39 (-2.11%)
Vascular Biogenics (VBLT) Reports Q2 Loss, Lags Revenue Estimates

Vascular Biogenics (VBLT) delivered earnings and revenue surprises of 27.78% and -40.00%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?

VBLT : 1.39 (-2.11%)
Vascular Biogenics: 2Q Earnings Snapshot

MODI'IN, Israel (AP) _ Vascular Biogenics Ltd. (VBLT) on Thursday reported a loss of $4.1 million in its second quarter.

VBLT : 1.39 (-2.11%)
VBL Therapeutics Announces Second Quarter 2018 Financial Results

Conference Call and Webcast at 8:30am Eastern Time Today

VBLT : 1.39 (-2.11%)
Vascular Biogenics Ltd. to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / August 16, 2018 / Vascular Biogenics Ltd. (NASDAQ: ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 16, 2018 at 8:30 AM Eastern Time....

VBLT : 1.39 (-2.11%)
VBL Therapeutics to Report Second Quarter 2018 Financial Results on August 16

VBL Therapeutics (Nasdaq:VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class treatments for cancer, today announced that it will...

VBLT : 1.39 (-2.11%)
Publication by VBL Therapeutics Highlights MOSPD2 as a Potential New Target for Breast Cancer Therapy

Paper on Role of MOSPD2 in Metastatic Breast Cancer Published in International Journal of Cancer

VBLT : 1.39 (-2.11%)
Vascular Biogenics: 1Q Earnings Snapshot

OR YEHUDA, Israel (AP) _ Vascular Biogenics Ltd. (VBLT) on Thursday reported a loss of $7.2 million in its first quarter.

VBLT : 1.39 (-2.11%)
VBL Therapeutics to Present Data on its MOSPD2 Oncology Program at MIXiii-BIOMED 2018 on May 15

VBL Therapeutics (Nasdaq:VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class treatments for cancer, today announced that it will...

VBLT : 1.39 (-2.11%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Trade VBLT with:

Business Summary

Vascular Biogenics Ltd. is a clinical stage biotechnology company. It is focused on the discovery, development and commercialization of treatments for cancer and immune-inflammatory diseases. Its lead oncology candidate VB-111, is a gene-based biologic which is in Phase II clinical trials for the treatment...

See More

Key Turning Points

2nd Resistance Point 1.58
1st Resistance Point 1.49
Last Price 1.39
1st Support Level 1.31
2nd Support Level 1.22

See More

52-Week High 9.05
Fibonacci 61.8% 6.10
Fibonacci 50% 5.18
Fibonacci 38.2% 4.27
Last Price 1.39
52-Week Low 1.32

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar